When the national guidelines were revised in 2022, treatment eligibility criteria were expanded (specifically, the alanine transaminase [ALT] level indicating antiviral treatment was reduced from 80 to 40 U/L for patients with mild or no fibrosis [8]). Here, GPT is linked to fibrosis.